RxStrategies, Inc.

Clinical Insights: November 2, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Tecvayli™ (teclistamab-cqyv) Injection – New Drug Approval – October 25, 2022 – The Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™, Janssen Biotech, Inc.), the first bispecific B-cell…

Read More...

Clinical Insights: October 26, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Imjudo® (tremelimumab-actl) Injection – New Drug Approval – October 24, 2022 – AstraZeneca’s Imjudo® (tremelimumab) in combination with Imfinzi® (durvalumab) has been approved in the US for the treatment…

Read More...

Clinical Insights: October 19, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Menveo® (meningococcal conjugate vaccine) – New Label Expansion – October 14, 2022 – GSK plc announced that the US Food and Drug Administration…

Read More...

RxStrategies to Attend the 2022 FOM/IT Conference & Expo

RxStrategies will be at the 2022 (Financial, Operations Management / Information Technology) FOM/IT Conference & Expo, October 29-31 in Las Vegas, NV. Our team is looking forward to connecting and sharing about our intuitive 340B solutions. Stop by Booth #716 to meet with Rhodie Smith and Kathy Sauerland at the Expo on October 30-31. See the floor-plan. Schedule a platform…

Read More...

Celebrating the Impact and Contributions of the Pharmacy Field

Pharmacists, pharmacy technicians and staff provide incredible support to quality patient care in hospitals, health centers, pharmacies and other settings. Today and every day, we recognize and honor them for such invaluable contributions.   Happy National Pharmacy Week!

Read More...

Clinical Insights: October 12, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Furoscix® (furosemide injection) – New Drug Approval – October 11, 2022 – The FDA has approved scPharmaceuticals’ Furoscix® (furosemide injection) for treatment of congestion due to fluid overload in…

Read More...

Connect with RxStrategies at the 2022 Fall Hospital Pharmacy Conference

RxStrategies will be attending the 2022 Fall Hospital Pharmacy Conference in person and virtually. Connect with our team members and learn about our 340B solutions. Meet with Rhodie Smith in person at the Reverse Expo on October 24-26. Connect with Heidi Ryan at the Live-Online on November 14-25 to learn more about our 340B solutions…

Read More...

Clinical Insights: October 5, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lytgobi® (futibatinib) Tablets – New Drug Approval – September 30, 2022 – The Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi®, Taiho Oncology, Inc.) for adult patients…

Read More...

Clinical Insights: September 28, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Pedmark® (sodium thiosulfate) – New Drug Approval – September 20, 2022 – On September 20, 2022, the Food and Drug Administration approved sodium thiosulfate (Pedmark®, Fennec Pharmaceuticals Inc.) to…

Read More...

Clinical Insights: September 21, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Skysona® (elivaldogene autotemcel) Suspension for Intravenous Infusion – New Drug Approval – September 16, 2022 – bluebird bio, Inc. announced the U.S. Food and Drug Administration (FDA) has granted…

Read More...

Clinical Insights: September 14, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sotyktu™ (deucravacitinib) Tablets – New Drug Approval – September 9, 2022 – Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class,…

Read More...

Clinical Insights: September 7, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Konvomep™ (omeprazole and sodium bicarbonate) Powder for Oral Suspension – New Drug Approval – September 2, 2022 – Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative dose-forms…

Read More...